دورية أكاديمية
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.
| العنوان: | Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. |
|---|---|
| المؤلفون: | de Matos Simoes R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Shirasaki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Downey-Kopyscinski SL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Matthews GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Barwick BG; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Gupta VA; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Dupéré-Richer D; University of Florida Health Cancer Center, Gainesville, FL, USA., Yamano S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Hu Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sheffer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Dhimolea E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Dashevsky O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Gandolfi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Ishiguro K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Meyers RM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Bryan JG; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dharia NV; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hengeveld PJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Brüggenthies JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Sievers QL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Glassner BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Ott CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Kwiatkowski NP; Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Levy J; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Keats JJ; Translational Genomics Research Institute, Phoenix, AZ, USA., Groen RWJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Gray NS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Culhane AC; Department of Data Sciences, Dana-Farber Cancer Institute & Harvard School of Public Health, Boston, MA, USA.; Limerick Digital Cancer Research Center, Health Research Institute, School of Medicine, University of Limerick, Limerick, Ireland., McFarland JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dempster JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA., Boise LH; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Vazquez F; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. vazquez@broadinstitute.org., Tsherniak A; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. aviad@broadinstitute.org., Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Ludwig Center at Harvard, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu. |
| المصدر: | Nature cancer [Nat Cancer] 2023 May; Vol. 4 (5), pp. 754-773. Date of Electronic Publication: 2023 May 26. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Nature Publishing Group, [2020]- |
| مواضيع طبية MeSH: | Multiple Myeloma*/genetics, Humans ; Genomics ; Genome ; Clustered Regularly Interspaced Short Palindromic Repeats/genetics |
| مستخلص: | Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC neoplasias and do not target specific oncogenic mutations in MM. Instead, these agents target pathways critical for PC biology yet largely dispensable for malignant or normal cells of most other lineages. Here we systematically characterized the lineage-preferential molecular dependencies of MM through genome-scale clustered regularly interspaced short palindromic repeats (CRISPR) studies in 19 MM versus hundreds of non-MM lines and identified 116 genes whose disruption more significantly affects MM cell fitness compared with other malignancies. These genes, some known, others not previously linked to MM, encode transcription factors, chromatin modifiers, endoplasmic reticulum components, metabolic regulators or signaling molecules. Most of these genes are not among the top amplified, overexpressed or mutated in MM. Functional genomics approaches thus define new therapeutic targets in MM not readily identifiable by standard genomic, transcriptional or epigenetic profiling analyses. (© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.) |
| References: | J Med Chem. 2016 Oct 13;59(19):9124-9139. (PMID: 27584694) Blood. 2012 Jul 19;120(3):e9-e16. (PMID: 22653974) Nat Med. 2010 Apr;16(4):483-9. (PMID: 20228816) Nat Rev Drug Discov. 2013 Mar;12(3):217-28. (PMID: 23449307) Science. 2014 Jan 17;343(6168):301-5. (PMID: 24292625) Nat Biotechnol. 2020 Jun;38(6):675-678. (PMID: 32444850) Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9. (PMID: 12391322) Cell. 2017 Jul 27;170(3):564-576.e16. (PMID: 28753430) Sci Data. 2014 Sep 30;1:140035. (PMID: 25984343) Nat Commun. 2016 Jun 10;7:11786. (PMID: 27283361) Front Immunol. 2019 May 21;10:1121. (PMID: 31231360) Nature. 2012 Mar 28;483(7391):603-7. (PMID: 22460905) Nature. 2014 Aug 7;512(7512):49-53. (PMID: 25043012) Leukemia. 2019 Dec;33(12):2924-2933. (PMID: 31092894) Cell Rep. 2021 Jan 5;34(1):108532. (PMID: 33406420) Blood. 2014 Sep 18;124(12):1873-9. (PMID: 25097176) Oncogene. 2008 Jan 3;27(1):63-75. (PMID: 17621271) Blood. 2017 Mar 9;129(10):1284-1295. (PMID: 28053195) Mol Cancer Res. 2018 Jul;16(7):1138-1148. (PMID: 29592898) Nat Commun. 2018 Nov 2;9(1):4610. (PMID: 30389920) Leuk Lymphoma. 2011 Apr;52(4):659-67. (PMID: 21438833) J Med Chem. 2016 Jul 28;59(14):6838-47. (PMID: 27390919) Nat Chem Biol. 2020 Nov;16(11):1208-1217. (PMID: 32958952) Nature. 2008 Jul 10;454(7201):226-31. (PMID: 18568025) Blood. 2017 Mar 9;129(10):1308-1319. (PMID: 28082445) Genome Biol. 2014;15(12):554. (PMID: 25476604) Blood. 2018 Nov 15;132(20):2166-2178. (PMID: 30228232) Mol Cell. 2018 Mar 15;69(6):1017-1027.e6. (PMID: 29526696) Cancer Cell. 2004 Mar;5(3):221-30. (PMID: 15050914) Nat Chem Biol. 2018 May;14(5):431-441. (PMID: 29581585) Blood. 2012 Apr 12;119(15):e131-8. (PMID: 22289890) Haematologica. 2019 Jan;104(1):155-165. (PMID: 30171029) Cell. 2013 Apr 11;153(2):307-19. (PMID: 23582322) Nat Med. 2016 Jul;22(7):735-43. (PMID: 27294876) Blood. 2006 Jun 15;107(12):4907-16. (PMID: 16507771) Elife. 2018 Aug 01;7:. (PMID: 30067223) Cancer Discov. 2015 May;5(5):OF4. (PMID: 25802326) Genome Biol. 2008;9(9):R137. (PMID: 18798982) Genome Biol. 2014 Feb 03;15(2):R29. (PMID: 24485249) Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61. (PMID: 23180760) Nature. 2012 Jan 5;481(7379):90-3. (PMID: 22113614) Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10625-30. (PMID: 27601648) Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14592-7. (PMID: 22912405) J Biol Chem. 2001 Aug 17;276(33):30686-93. (PMID: 11402025) J Biol. 2003;2(4):28. (PMID: 14511394) Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886) Nat Med. 2016 Jul;22(7):727-34. (PMID: 27294874) Mol Cell. 2008 Mar 14;29(5):541-51. (PMID: 18342602) Cancer Discov. 2013 Aug;3(8):862-9. (PMID: 23612012) J Exp Med. 2006 Feb 20;203(2):311-7. (PMID: 16492805) Nat Commun. 2019 Apr 23;10(1):1911. (PMID: 31015454) Sci Rep. 2019 Jun 27;9(1):9354. (PMID: 31249361) Nat Genet. 2021 Aug;53(8):1196-1206. (PMID: 34253920) Lancet Oncol. 2020 Dec;21(12):1630-1642. (PMID: 33129376) Nat Rev Dis Primers. 2016 May 26;2:16035. (PMID: 27226234) Nat Genet. 2017 Dec;49(12):1779-1784. (PMID: 29083409) Cell. 2017 Jul 27;170(3):577-592.e10. (PMID: 28753431) Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368. (PMID: 27924014) Blood Cancer Discov. 2020 Nov;1(3):258-273. (PMID: 33392515) J Med Chem. 2018 Jan 25;61(2):535-542. (PMID: 28425720) Science. 2014 Jan 17;343(6168):305-9. (PMID: 24292623) Mol Cell. 2021 Mar 18;81(6):1170-1186.e10. (PMID: 33571422) Nat Struct Mol Biol. 2017 Oct;24(10):834-839. (PMID: 28869608) Science. 2018 Nov 2;362(6414):. (PMID: 30385546) Nat Commun. 2017 May 22;8:15398. (PMID: 28530236) Sci Rep. 2017 Dec 21;7(1):17993. (PMID: 29269946) Leuk Lymphoma. 2017 Sep;58(9):2196–2207. (PMID: 28142295) Nature. 2017 Mar 9;543(7644):270-274. (PMID: 28241139) |
| معلومات مُعتمدة: | R01 CA276156 United States CA NCI NIH HHS; R01 CA192844 United States CA NCI NIH HHS; R01 CA179483 United States CA NCI NIH HHS; U01 CA176058 United States CA NCI NIH HHS; R01 CA180475 United States CA NCI NIH HHS; L30 CA231673 United States CA NCI NIH HHS; T32 GM007753 United States GM NIGMS NIH HHS; R01 CA196664 United States CA NCI NIH HHS; U01 CA225730 United States CA NCI NIH HHS; R01 CA050947 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20230526 Date Completed: 20230529 Latest Revision: 20240527 |
| رمز التحديث: | 20240527 |
| مُعرف محوري في PubMed: | PMC10918623 |
| DOI: | 10.1038/s43018-023-00550-x |
| PMID: | 37237081 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. | تدمد: | 2662-1347 |
|---|---|
| DOI: | 10.1038/s43018-023-00550-x |